Menu Close

Trending

Diving deeper into AI discovery, Sanofi signs 5-drug deal with Atomwise
GSK gets June 2023 FDA decision date for momelotinib
End of the line for Sanofi’s SERD amcenestrant as it fails first-line trial
Key Presentations at the Medical Devices & IVD Conference Released
Respiratory Monitoring & AI Technologies

Views & Analysis

Cancer research faces uncertain post-COVID landscape

Deep Dive/ Oncology/ Views & Analysis/ Views and analysis

Cancer research faces uncertain post-COVID landscape

, , , , , , 0 Comment

There’s a bright future ahead for cancer research in the UK, but only if the government is able

X
Cancer research faces uncertain post-COVID landscape
https://pharmaphorum.com/views-analysis-oncology/cancer-research-faces-uncertain-post-covid-landscape/
Lessons from the first generation of cell and gene oncology trials

Deep Dive/ Oncology/ Views & Analysis/ Views and analysis

Lessons from the first generation of cell and gene oncology trials

, , , , , , 0 Comment

Advances in cell and gene science are paving the way for transformative cancer treatments, but there are still

X
Lessons from the first generation of cell and gene oncology trials
https://pharmaphorum.com/views-analysis-oncology/lessons-from-the-first-generation-of-cell-and-gene-oncology-trials/
Oncology R&D: the patient insights we’re still missing, and how to catch up

Deep Dive/ Oncology/ Views & Analysis/ Views and analysis

Oncology R&D: the patient insights we’re still missing, and how to catch up

, , , , , 0 Comment

Imagine you are a pharma executive working in oncology R&D. The landscape is rapidly becoming more competitive and

X
Oncology R&D: the patient insights we’re still missing, and how to catch up
https://pharmaphorum.com/views-analysis-oncology/81949/
Digital tools key to immuno-oncology’s future: report

Deep Dive/ Oncology/ Views & Analysis/ Views and analysis

Digital tools key to immuno-oncology’s future: report

, , , , , 0 Comment

If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows

X
Digital tools key to immuno-oncology’s future: report
https://pharmaphorum.com/views-analysis-oncology/digital-tools-key-to-immuno-oncologys-future-report/
Oncology and a year of COVID: lessons for the future

Deep Dive/ Oncology/ Views & Analysis/ Views and analysis

Oncology and a year of COVID: lessons for the future

, , , , , , , 0 Comment

COVID’s impact on cancer care and oncology research has been devastating, but the pandemic has also opened up

X
Oncology and a year of COVID: lessons for the future
https://pharmaphorum.com/views-analysis-oncology/oncology-and-a-year-of-covid-lessons-for-the-future/
How hybrid virtual engagement is accelerating oncology communication

Deep Dive/ Oncology/ Views & Analysis/ Views and analysis

How hybrid virtual engagement is accelerating oncology communication

, , , , , , , , 0 Comment

COVID has revolutionised the way pharma engages with healthcare stakeholders – but to be truly successful, digital engagement

X
How hybrid virtual engagement is accelerating oncology communication
https://pharmaphorum.com/views-analysis-oncology/how-hybrid-virtual-engagement-is-accelerating-oncology-communication/
«‹ 3 4 5 6 ›»

Login

CONTINUE TO SITE >
X
Close in 10 seconds